First Time Loading...

Circassia Group PLC
LSE:CIR

Watchlist Manager
Circassia Group PLC Logo
Circassia Group PLC
LSE:CIR
Watchlist
Price: 36.5 GBX 0.83% Market Closed
Updated: May 4, 2024

Profitability Summary

Circassia Group PLC's profitability score is 58/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

58/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

58/100
Profitability
Score
58/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Circassia Group PLC

Revenue
31.3m GBP
Cost of Revenue
-9.1m GBP
Gross Profit
22.2m GBP
Operating Expenses
-20.4m GBP
Operating Income
1.8m GBP
Other Expenses
14.3m GBP
Net Income
16.1m GBP

Margins Comparison
Circassia Group PLC Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
UK
Circassia Group PLC
LSE:CIR
153.1m GBP
71%
6%
51%
US
Abbvie Inc
NYSE:ABBV
289.2B USD
66%
30%
9%
US
Amgen Inc
NASDAQ:AMGN
166.7B USD
70%
29%
24%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
104.7B USD
86%
32%
30%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.4B USD
87%
39%
37%
AU
CSL Ltd
ASX:CSL
133.2B AUD
52%
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
80.7B USD
76%
32%
2%
US
Moderna Inc
NASDAQ:MRNA
47.8B USD
31%
-62%
-69%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
75%
-33%
-33%
US
Biogen Inc
NASDAQ:BIIB
31.7B USD
75%
22%
12%
KR
Celltrion Inc
KRX:068270
39.2T KRW
48%
30%
25%
Country UK
Market Cap 153.1m GBP
Gross Margin
71%
Operating Margin
6%
Net Margin
51%
Country US
Market Cap 289.2B USD
Gross Margin
66%
Operating Margin
30%
Net Margin
9%
Country US
Market Cap 166.7B USD
Gross Margin
70%
Operating Margin
29%
Net Margin
24%
Country US
Market Cap 104.7B USD
Gross Margin
86%
Operating Margin
32%
Net Margin
30%
Country US
Market Cap 103.4B USD
Gross Margin
87%
Operating Margin
39%
Net Margin
37%
Country AU
Market Cap 133.2B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 80.7B USD
Gross Margin
76%
Operating Margin
32%
Net Margin
2%
Country US
Market Cap 47.8B USD
Gross Margin
31%
Operating Margin
-62%
Net Margin
-69%
Country US
Market Cap 43.1B USD
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 31.7B USD
Gross Margin
75%
Operating Margin
22%
Net Margin
12%
Country KR
Market Cap 39.2T KRW
Gross Margin
48%
Operating Margin
30%
Net Margin
25%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Circassia Group PLC Competitors

Country Company Market Cap ROE ROA ROCE ROIC
UK
Circassia Group PLC
LSE:CIR
153.1m GBP
21%
17%
2%
3%
US
Abbvie Inc
NYSE:ABBV
289.2B USD
35%
4%
16%
13%
US
Amgen Inc
NASDAQ:AMGN
166.7B USD
136%
8%
13%
11%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
104.7B USD
16%
13%
15%
32%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.4B USD
23%
18%
22%
44%
AU
CSL Ltd
ASX:CSL
133.2B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
80.7B USD
3%
1%
18%
7%
US
Moderna Inc
NASDAQ:MRNA
47.8B USD
-29%
-21%
-23%
-41%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Biogen Inc
NASDAQ:BIIB
31.7B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
39.2T KRW
5%
4%
6%
4%
Country UK
Market Cap 153.1m GBP
ROE
21%
ROA
17%
ROCE
2%
ROIC
3%
Country US
Market Cap 289.2B USD
ROE
35%
ROA
4%
ROCE
16%
ROIC
13%
Country US
Market Cap 166.7B USD
ROE
136%
ROA
8%
ROCE
13%
ROIC
11%
Country US
Market Cap 104.7B USD
ROE
16%
ROA
13%
ROCE
15%
ROIC
32%
Country US
Market Cap 103.4B USD
ROE
23%
ROA
18%
ROCE
22%
ROIC
44%
Country AU
Market Cap 133.2B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 80.7B USD
ROE
3%
ROA
1%
ROCE
18%
ROIC
7%
Country US
Market Cap 47.8B USD
ROE
-29%
ROA
-21%
ROCE
-23%
ROIC
-41%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 31.7B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 39.2T KRW
ROE
5%
ROA
4%
ROCE
6%
ROIC
4%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More